Navigation Links
Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
Date:3/16/2009

t response of treated lesions may be a good predictor of long-term outcome."

Professor Thompson added, "The interim Phase 2 results are also very encouraging, with efficacy and safety as good as or better than those results reported for Phase 1. With the Phase 2 protocol allowing us to treat lesions more than once, we are pleased to report results that are in line with what our expectations have been."

Dr. Craig Dees, PhD, CEO of Provectus concluded, "We are encouraged by these Phase 2 interim results as well as by the improved long-term survival data from Phase 1. With the American Cancer Society estimating that approximately 120,000 patients in the U.S. alone have metastatic melanoma, and the World Health Organization reporting that about 48,000 patients died around the globe from melanoma in 2008, clearly there is a need for a new safe and effective treatment for metastatic melanoma. We look forward to furthering this important research on PV-10 and to communicating detailed Phase 2 interim results at ASCO."

About PV-10

PV-10 is based on a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly fifty years by ophthalmologists and optometrists to assess damage to the eye. It has also been used to detect ailments of the liver. Rose Bengal has an established safety history, a short half-life, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis.

About The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies

The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies, an Oncology CME-Certified Symp
'/>"/>

SOURCE Provectus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22 2015 /CNW/ - The Taskforce representing ... appreciative of all the hard work that the Minister and ... six months. This program recognizes the needs of the thalidomide ... least $75,000 a year, tax free, with annual adjustments for ... eligible for annual payments of $100,000 based on the severity ...
(Date:5/22/2015)... Solutions, Inc. (NASDAQ: BLFS ), a leading developer, manufacturer ... and cryopreservation freeze media and precision thermal ... "Company"), announced that the Company is scheduled to present at ... is scheduled to present at the Conference at 1:30 p.m. ... Hotel in New York City and ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... Dear President-Elect Obama:, , ... billions of dollars,earmarked for stem cell research. As spokesman ... of the Repair Stem Cell research and,treatment industry worldwide, I ... our industry and the medical and scientific professionals,hospitals, treatment centers ...
... Tenn., Nov. 24 A new cancer treatment ... weeks,of treatment, a patient,s large, stage 4 tumor ... weeks of treatment, it no longer could be ... six to nine months,after diagnosis. NeoPlas Innovation,s combination ...
Cached Medicine Technology:Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2New Cancer Treatment Shrinks Pancreatic Tumor 2
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... OH (PRWEB) May 22, 2015 River ... that Kyle Johnson, the health system’s Chief Financial Officer ... interests. Johnson has served as the company CFO since ... West will be joining the health system as CFO. ... an interim basis, while the Board of Trustees conducts ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... from the Children,s Cancer Hospital at The University of Texas ... to more accurately predict treatment outcomes in young leukemia patients ... test, also known as a CBC. The results ... of Pediatric Hematology Oncology,s (ASPHO) annual meeting today. The study ...
... or friends, survey finds , FRIDAY, April 9 (HealthDay News) ... most likely to sexually abuse children when, in fact, relatives ... By doing so, parents may be failing to give their ... it happens and try to stop it, the study authors ...
... ... the issue of “medication adherence.” , ... Alexandria, VA (Vocus) April 10, 2010 -- An article in the ... the National Association of Chain Drug Stores’ (NACDS) message that pharmacy’s role in helping ...
... in the United States has experienced a conflict with ... patient care, researchers from the University of Chicago report ... Journal of General Internal Medicine . Younger and ... conflicts than their older or more religious peers. Most ...
... early recover faster, reduce sedative use, research shows , FRIDAY, ... intensive care unit may reduce their use of sedatives and ... study has found. , The amount of prescription sedatives had ... which reduced the amount of muscle weakness caused by spending ...
... ... Equals a Charitable Donation to Further the Safe Handling of Hazardous Drugs , ... COLUMBUS, OH (Vocus) April ... “Safe Handling Dance”? In recognition of National Safe Handling Awareness Month (April), Carmel Pharma, ...
Cached Medicine News:Health News:M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients 2Health News:Kids Often Misled About Child Abuse 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 3Health News:Primary care physicians nationwide face clinical ethical conflicts with religious hospitals 2Health News:Mild Exercise Good for the Critically Ill 2Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 2Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 3Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 4Health News:Now Live! The “Safe Handling Dance” Video to Benefit ASHP/ONS Foundations 5
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... Utilizing technology developed over Guidants 20-year ... the new foundation for successful treatment outcomes. ... tip design with a lower profile shaft,more ... Now you can cross tight and tortuous ...
Test for AFP...
Test for AFP...
Medicine Products: